Cognitive impairment after acute encephalitis: comparison of herpes simplex and other aetiologies

Laura Hokkanen, Erja Poutiainen, Leena Valanne, Oili Salonen, M Ivivanainen, Jyrki Launes

Abstract
Objective—To compare the cognitive defects after acute acyclovir treated herpes simplex encephalitis with those after other types of acute encephalitis.
Methods—Seventy seven consecutive patients between 1985 and 1995 and 29 normal controls were studied. Of the 77 patients without concomitant neurological conditions, 17 had herpes simplex, one virus encephalitis (HSVE group), 27 had some other identified aetiology (non-HSVE group), and in 33 patients the cause was unknown. Acyclovir treatment was started less than four days after the first mental symptoms in 12 of 17 patients with HSVE. A thorough neuropsychological assessment was carried out about one month after the onset.
Results—The HSVE group had deficits in verbal memory, verbal-semantic functions, and visuoperceptual functions more often than the non-HSVE group. The risk for cognitive defects was twofold to fourfold in the patients with HSVE compared with the non-HSVE patients. Two (12%) of the patients with HSVE and 12 (44%) of the non-HSVE patients were cognitively intact. Six patients with HSVE (46%) and 17 (89%) non-HSVE patients later returned to work. The lesions on CT or MRI were bilateral only in one patient with HSVE. The defects in the three patients with adenovirus infection were severe and resembled the amnesia after HSVE. Cognitive impairment, not previously reported, was found in encephalitis after rotavirus infection and epidemic nephropathy.
Conclusion—The recovery in the HSVE group was better than expected based on the medical literature. On the other hand there were surprisingly severe cognitive defects in encephalitis after other viruses. With early acyclovir treatment patients with the least severe HSVE were equivalent to those with non-HSVE encephalitis with good outcome whereas those with the most severe non-HSV encephalitis were equivalent to those with HSVE with poor outcome.

(J Neurol Neurosurg Psychiatry 1996;61:478–484)

Keywords: encephalitis; cognitive performance; herpes simplex

Acute encephalitis is an inflammation of the brain parenchyma, in most patients caused by viral agents, although bacterial, other microbial, and postinfectious forms are known. In the United States 20,000 cases occur each year. In Finland the prevalence of meningoencephalitis and encephalitis is estimated to be 3.5 cases per 100,000. The aetiology may be difficult to determine and one third to two thirds of the patients lack specific microbial confirmation. Worldwide, the arboviruses are the most frequent cause of epidemics of encephalitis. In Western Europe sporadic infections account for most cases, and the most common single aetiology is herpes simplex 1 virus. In Sweden the incidence of herpes simplex encephalitis (HSVE) is at least 2.3 cases per million inhabitants per year.

Mental changes as an initial consequence of encephalitis have been reported in all epidemiological studies. The cognitive defects that persist after the acute stage have seldom been reported in detail. In studies from the United States, the United Kingdom, and Germany the frequency of residual neurological disability has been 10%–30%, including aphasia, mental deterioration, and paralysis. Neuropsychological investigation was not used in any of these studies.

It has been reported that HSVE results in bilateral temporal lobe damage and persistent memory defect. The outcome has been considered poor; death or severe disablment and dependency being the common end points. Most of the reported cases originate from the 1970s and early 1980s, and since then acyclovir treatment has changed the prognosis of this disease. Early treatment may have an effect on the long term neuropsychological symptomatology as well, but only small series have so far been published.

Even fewer reports have described the neuropsychological findings in acute encephalitis of other aetiologies. In the United States, HSVE accounts for 5%–10% of the annual cases of encephalitis. In the German series of 53 patients with acute encephalitis, the most common aetiology, HSVE, was identified in nine patients, but 83% were either caused by other specified agents or were unidentified.

We studied the cognitive sequelae in 77 patients with acute encephalitis between 1985 and 1995.

Material and methods

PATIENT GROUPS AND CONTROLS

Between 1 January 1985 and 31 December 1994, 92 consecutive adult patients under the
Cognitive impairment after acute encephalitis: comparison of herpes simplex and other aetiologies

Table 1  Diagnostic methods for determining the specific aetiologies of 44 patients with encephalitis

<table>
<thead>
<tr>
<th>Aetiology</th>
<th>n</th>
<th>CSF or EIA, positive PCR in one day</th>
<th>CSF or EIA, and pathological s/CSF</th>
<th>Serum</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herpes simplex 1</td>
<td>12</td>
<td>CF or EIA</td>
<td>CF or EIA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>High ab titre</td>
<td>and pathological s/CSF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella zoster</td>
<td>4</td>
<td>CF or EIA</td>
<td>High ab titre</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>High ab titre</td>
<td>and pathological s/CSF</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Influenza B</td>
<td>2</td>
<td>High ab titre</td>
<td>High ab titre</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>M pneumoniae</td>
<td>1</td>
<td>Mycoplasma RNA in CSF</td>
<td>High ab titre</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rubella</td>
<td>2</td>
<td>IgM positive</td>
<td>High ab titre</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tick borne encephalitis</td>
<td>2</td>
<td>High ab titre, IgM positive</td>
<td>High ab titre</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenovirus</td>
<td>1</td>
<td>EIA</td>
<td>High ab titre</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td></td>
<td>and pathological s/CSF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenovirus + borreliosis</td>
<td>1</td>
<td>High ab titre for both</td>
<td>High ab titre, decline in ab titles</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td>2</td>
<td>High ab titre</td>
<td>High ab titre, positive IgM or</td>
<td>Genital lesions</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>electron microscopy</td>
<td>and positive culture</td>
<td></td>
</tr>
<tr>
<td>Herpes simplex 2</td>
<td>1</td>
<td>High ab titre</td>
<td>EIA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cryptococcus imanoni</td>
<td>1</td>
<td>Positive antigen test</td>
<td>EIA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epidemic nephropathy (</td>
<td>1</td>
<td>High ab titre</td>
<td>EIA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Puumala virus)</td>
<td></td>
<td></td>
<td>and pathological s/CSF</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CF = fourfold increase in the antibody titre in paired samples using the complement fixation test; EIA = twofold increase in the antibody titre in paired samples using the enzyme linked immunosorbent assay; PCR = polymerase chain reaction; ab = antibody; s/CSF = serum/CSF ratio.

age of 75 with acute encephalitis were referred for neuropsychological examination at the Department of Neurology, Helsinki University Central Hospital. It is the only hospital with 24 hour neurological emergency services in the province of Uusimaa (population 1 million), and thus the material includes nearly all adult patients with serious CNS infections in this area during this time. The diagnosis of encephalitis was based on the history, clinical physical and mental findings, and EEG suggesting involvement of the brain parenchyma, findings compatible with infection of the CNS, and CT excluding other causes. Fifteen patients with alcohol misuse, or coexisting or previous neurological disease were excluded. Thus 77 patients with acute encephalitis without concomitant conditions were analysed.

The aetiology was established in 44 (57%). The analyses were carried out at the Department of Virology, University of Helsinki. Table 1 gives the methods for reaching specific diagnoses. The polymerase chain reaction (PCR) method for the detection of herpes simplex virus-DNA was used in nine patients during 1993-4. Seventeen patients had herpes simplex 1 virus encephalitis (HSVE), nine had varicella zoster virus encephalitis (VZVE), and one had herpes simplex 2 virus (HSV-2) encephalitis. Seventeen had some other identified non-herpetic aetiology as the underlying cause for the encephalitis. The patients were grouped as the HSVE group (n = 17), the non-HSVE group (n = 27), and the unspecified group (n = 33).

Follow up EEG and standard laboratory tests were performed on all patients. Neuroradiological follow up was performed using CT in 18 patients and MRI in 31 patients. For analysis, the CT and MRI were scored blindly by two neuroradiologists (OS and LV). In the first CT, which was performed within the first three days in most patients, cortical or central atrophy was found in 16 of 77 patients (20%). At follow up, CT or MRI disclosed newly developed focal atrophy or focal lesions in 28 (36%) patients.

All patients received specific antibiotic treatment. Along with other medication, 73, including all patients with HSVE, were given intravenous acyclovir (30 mg/kg per day) for a mean of 11-2 (SD 4-1) days. One patient with influenza B, one with tick borne encephalitis virus, one with epidemic nephropathy, and one with suspicion of tuberculous meningoencephalitis were treated accordingly, without acyclovir medication. In the HSVE group acyclovir treatment was started on the same day as the mental symptoms appeared in two patients, on the next day in five patients, on day 2 in three patients, on day 3 in one patient, on day 4 in one patient, and five or more days after the onset in five patients.

The duration of stay in hospital was 36-4 (SD 38-2), range 8-213 days. After that the patients visited the hospital if necessary. The follow up extended up to the time of subsequent return to work or a decision to retire, maximally one year.

The performance of the patients in the neuropsychological investigation was compared with that of a group of 29 normal controls. Twenty five of the controls had initially volunteered for a study of quantitative EEG (Q-EEG) and were later willing to participate further. One control was excluded due to a history of probable meningitis. The others had no medical problems and their Q-EEG was normal. Five of the controls were additional volunteers who had no medical complaints and whose neurological examination was normal.

Table 2 shows distributions of age, sex, and education for the HSVE, non-HSVE, and the control groups. There was no difference in age.
or duration of education between the three groups (analysis of variance, ANOVA). There was a difference in the Beck depression inventory (BDI) score at the time of the neuropsychological investigation (mean 7.2 (7.8) in the HSVE group, 6.9 (7.8) in the non-HSVE group, 2.0 (2.4) in the control group, F = 5.18, P < 0.01). Pairwise post hoc analyses disclosed a higher depression score in patients than in controls (P < 0.02, Tukey's honest significant difference), but no difference between the HSVE and the non-HSVE groups. There was no difference in the age, age of onset, and sex between the two groups.

**NEUROPSYCHOLOGICAL ASSESSMENT**

The neuropsychological examination was carried out in a postacute stage, as soon as the initial confusion had subsided and the patient could cooperate adequately. This was a mean 27.5 (27.8) range 5–128 days, after the onset of symptoms. The controls underwent a similar neuropsychological examination.

### Table 2 Sex, age, and education of the patients and the controls, and location of focal findings in follow up CT or MRI in HSVE, non-HSVE, and control groups

<table>
<thead>
<tr>
<th></th>
<th>HSVE (n = 17)</th>
<th>non-HSVE (n = 27)</th>
<th>Controls (n = 29)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>8/9</td>
<td>16/11</td>
<td>11/18</td>
</tr>
<tr>
<td>Age (y)</td>
<td>50.2 (12.7)</td>
<td>38.7 (20.0)</td>
<td>44.4 (14.1)</td>
</tr>
<tr>
<td>Range</td>
<td>23-68</td>
<td>17-73</td>
<td>21-78</td>
</tr>
<tr>
<td>Education</td>
<td>10-9 (4.3)</td>
<td>11-2 (3.7)</td>
<td>12-9 (3.1)</td>
</tr>
</tbody>
</table>

**Values for age and education are means (SD).**

1. Patient with varicellar zoster viral encephalitis.
2. Patient with varicellar zoster viral encephalitis.
3. Patient with Mycoplasma pneumoniae infection (patient 5).

The cognitive functions were evaluated in seven different areas. Verbal logical thinking was assessed using the Wechsler adult intelligence scale (WAIS) verbal intelligence quotient (VIQ) estimated by subtests information, arithmetic, and vocabulary or similarities. Visual logical thinking was assessed with the WAIS performance intelligence quotient (PIQ) estimated by subtests digit symbols, picture completion, and block design. Deficit was considered to exist if the VIQ or the PIQ fell below 95, the lower limit of the normal range in Finnish norms. Verbal memory was assessed with the Wechsler memory scale (WMS) subtests logical memory and associative learning, in which the raw scores were added together. Visual memory was assessed by adding together the raw scores of the WMS visual reproduction and the Benton visual retention test. Verbal-semantic functions were assessed with analysis of the overt speech and understanding of the instructions, confrontation naming of body parts and pictures of familiar objects, and comprehension of sentences with complex semantic structures.

### Table 3 Comparison of mean psychometric test results of the HSVE group, the non-HSVE group, and the controls

<table>
<thead>
<tr>
<th></th>
<th>HSVE (n = 17)</th>
<th>non-HSVE (n = 27)</th>
<th>Controls (n = 29)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VIQ</td>
<td>97.5 (25.7)</td>
<td>109.6 (16.8)</td>
<td>121.8 (12.5)</td>
</tr>
<tr>
<td>Range</td>
<td>37-138</td>
<td>72-130</td>
<td>104-152</td>
</tr>
<tr>
<td>PIQ</td>
<td>95.5 (21.3)</td>
<td>108.1 (15.2)</td>
<td>126-2 (13.2)</td>
</tr>
<tr>
<td>Range</td>
<td>74-143</td>
<td>144-116</td>
<td>150-159</td>
</tr>
<tr>
<td>Verbal memory</td>
<td>14-9 (4.3)</td>
<td>30-6 (6.0)</td>
<td>31-8 (4.5)</td>
</tr>
<tr>
<td>Range</td>
<td>2-15-9</td>
<td>14-36</td>
<td>22-5-38</td>
</tr>
<tr>
<td>Visual memory</td>
<td>12-6 (8.9)</td>
<td>31-3 (4.9)</td>
<td>35-4 (3.5)</td>
</tr>
<tr>
<td>Range</td>
<td>12-38</td>
<td>21-39</td>
<td>27-40</td>
</tr>
</tbody>
</table>

**Values in parentheses are SD.**

Significance measured by post hoc Tukey pairwise analysis.

### Results

Significant psychometric differences were found between the HSVE, the non-HSVE, and the control groups (ANOVA: VIQ F (2, 69) = 10.2, P < 0.001; PIQ F (2, 69) = 20.9, P < 0.001; verbal memory F (2, 66) = 38.8, P < 0.001; and visual memory F (2, 63) = 21.4, P < 0.001). In pairwise comparison (Tukey's honest significant difference, Sjostov/Stoline test), both the HSVE and the non-HSVE group performed worse than the controls in all tests (P < 0.05). In the verbal and the visual memory the HSVE group was more impaired than the non-HSVE group (P < 0.001). Table 3 gives the neuropsychological findings.
Table 4 gives the frequencies of cognitive deficits in HSVE and non-HSVE groups. The HSVE group had a higher frequency of deficits in all measures, and significant differences were found in verbal memory, verbal-semantic functions, and visuo perceptual functions. The risk of defects in the HSVE group was twofold to fourfold compared with the non-HSVE group (table 5). Two of the 17 patients with HSVE (12%), and 12 of 27 of the non-HSVE patients (44%) were cognitively intact. Eleven patients with HSVE (65%) had persisting mood or personality change as opposed to three (11%) non-HSVE patients (Pearson's $\chi^2 = 13.8$, $P<0.01$). These disturbances included euphoria and manic behaviour, aggressiveness and irritability, and depressive mood. No Klüver-Bucy type of behaviour was seen.

Table 5 presents the neuropsychological findings of patients with non-herpetic aetiology. Neuropsychological test performance of three of the four patients with encephalitis after an influenza B infection (patients 1–3), and both patients with Mycoplasma pneumoniae (patients 5–6), rubella (patients 7–8), and arbovirus (patients 9–10) encephalitis were rated intact. One patient with influenza B infection had slightly lowered VIQ and mild inaccuracy in visuo perceptual performance. The two patients with adenovirus infection and the one with simultaneous borreli and adenovirus infection (patients 11–13) all had a clear memory defect, as well as circumscribed neuropsychological findings, including verbal-semantic or visuo perceptual difficulty. One patient with rotavirus infection (patient 14) was inaccurate in visuo perceptual functions, the other (patient 15) had memory defects. Cryptococcal infection (patient 16) led to persistent epilepsy, slowness, general deterioration, and retirement. Epidemic nephropathy (patient 17) resulted in visuo perceptual difficulty and hand dyspraxia. Findings for patients with VZVE will be reported in detail separately, and are not discussed here. The patient with HSV-2 had marginal difficulty in attention and mild inaccuracy in visuo perceptual functions.

Two patients died of cancer but no deaths related to encephalitis occurred in this study population during the follow up period. Twenty nine patients with a non-specified aetiology (total n = 33) were employed before the onset of illness. Of these, 23 (73%) were able to return to their initial occupation. Thirty two patients with a specified aetiology (total n = 44) were employed before the onset of illness, and of those, 23 (72%) were able to return to work. The percentage of patients who were able to return to work was similar in the specified and non-specified group (Pearson's $\chi^2$ test). Six of the HSVE group (46% of the 13 who were employed) and 17 of the non-HSVE patients (89% of the 19 who were employed) returned to work after illness, which means a poorer outcome for the HSVE patients (Pearson's $\chi^2 = 7.2$, $P<0.01$). In patients with HSVE, the duration of sick leave was 133.5 (80-1), range 63–251 days, and in non-HSVE patients 84-2 (67-3), range 13–271 days, after the onset of symptoms (no difference by Student's $t$ test).

No differences in any of the cognitive measures were found between patients with a specified aetiology (both HSVE and non-

### Table 4 Occurrence of different cognitive deficits of the HSVE and non-HSVE groups and the increased risk for cognitive defects in the HSVE group

<table>
<thead>
<tr>
<th>Areas of cognitive defect</th>
<th>HSVE (n = 17) No (%)</th>
<th>Non-HSVE (n = 27) No (%)</th>
<th>Risk ratio (95% CI)</th>
<th>$\chi^2$ (P value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verbal logical thinking</td>
<td>7 (41)</td>
<td>6 (22)</td>
<td>1.67</td>
<td>1.00</td>
</tr>
<tr>
<td>Visual logical thinking</td>
<td>9 (53)</td>
<td>6 (22)</td>
<td>2.17</td>
<td>3.12</td>
</tr>
<tr>
<td>Verbal memory</td>
<td>13 (76)</td>
<td>8 (30)</td>
<td>3.56 (1.4–8.9)</td>
<td>7.2 (P &lt; 0.01)</td>
</tr>
<tr>
<td>Visual memory</td>
<td>10 (59)</td>
<td>9 (33)</td>
<td>1.88</td>
<td>0.81</td>
</tr>
<tr>
<td>Verbal-semantic</td>
<td>10 (59)</td>
<td>6 (22)</td>
<td>2.50 (1.1–5.8)</td>
<td>4.56 (P &lt; 0.05)</td>
</tr>
<tr>
<td>Visuo perceptual</td>
<td>14 (82)</td>
<td>11 (41)</td>
<td>3.55 (1.5–8.8)</td>
<td>5.74 (P &lt; 0.05)</td>
</tr>
<tr>
<td>Voluntary motor</td>
<td>3 (18)</td>
<td>3 (11)</td>
<td>1.36</td>
<td>0.03</td>
</tr>
<tr>
<td>Any cognitive defects</td>
<td>15 (88)</td>
<td>15 (56)</td>
<td>3.50</td>
<td>3.74</td>
</tr>
</tbody>
</table>

### Table 5 Neuropsychological findings in patients with non-herpetic encephalitis

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Aetiology</th>
<th>VIQ</th>
<th>PIQ</th>
<th>MQ</th>
<th>Verbal memory*</th>
<th>Visual memory*</th>
<th>Verbal-semantic*</th>
<th>Visuo perceptual*</th>
<th>Voluntary motor*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Influenza B</td>
<td>125</td>
<td>120</td>
<td>123</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>2</td>
<td>Influenza B</td>
<td>113</td>
<td>118</td>
<td>123</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>3</td>
<td>Influenza B</td>
<td>129</td>
<td>146</td>
<td>124</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>4</td>
<td>Influenza B</td>
<td>95</td>
<td>114</td>
<td>118</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>+</td>
</tr>
<tr>
<td>5</td>
<td>M pneumoniae</td>
<td>101</td>
<td>104</td>
<td>99</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>6</td>
<td>M pneumoniae</td>
<td>106</td>
<td>95</td>
<td>107</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>7</td>
<td>Rubella</td>
<td>122</td>
<td>116</td>
<td>118</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>8</td>
<td>Rubella</td>
<td>103</td>
<td>106</td>
<td>101</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>9</td>
<td>Arbovirus</td>
<td>130</td>
<td>112</td>
<td>150</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>10</td>
<td>Arbovirus</td>
<td>113</td>
<td>132</td>
<td>112</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>11</td>
<td>Adenovirus</td>
<td>77</td>
<td>82</td>
<td>83</td>
<td>+</td>
<td>n</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>12</td>
<td>Adenovirus</td>
<td>107</td>
<td>105</td>
<td>84</td>
<td>+</td>
<td>n</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>13</td>
<td>Adenovirus</td>
<td>110</td>
<td>106</td>
<td>81</td>
<td>+</td>
<td>n</td>
<td>+</td>
<td>+</td>
<td>n</td>
</tr>
<tr>
<td>14</td>
<td>Rotavirus</td>
<td>123</td>
<td>106</td>
<td>106</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>+</td>
</tr>
<tr>
<td>15</td>
<td>Rotavirus</td>
<td>116</td>
<td>116</td>
<td>88</td>
<td>+</td>
<td>n</td>
<td>+</td>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>16</td>
<td>Cryptococcus</td>
<td>85</td>
<td>91</td>
<td>77</td>
<td>+</td>
<td>n</td>
<td>+</td>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>17</td>
<td>Epidemic nephropathy</td>
<td>110</td>
<td>103</td>
<td>98</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>+</td>
</tr>
</tbody>
</table>

*The defined cut off point was 2SD below the mean of the controls. n = Normal range; +Infection in conjunction with borreliosis; + Abnormal finding in any of the test measuring the function.
HSVE, n = 44) and the patients with unspecified encephalitis (n = 33) analysed either by group means or frequencies of deficits.

**Discussion**

The cognitive deficits in patients with HSVE were more frequent as well as more severe than in those with non-HSVE. Intellectual functions and logical thinking were not statistically more impaired in patients with HSVE, but the HSVE group had more deficits in memory functions and in verbal-semantic and visuo-perceptual functions. In the postacute stage, the risk for cognitive deficits in HSVE was twofold to fourfold compared with a non-HSVE group. However, the variability was high, as the 95% confidence intervals of the risk ratios ranged from 1.1 to 9.0. Some patients with HSVE were cognitively intact. In a recent study, dense amnesia was found in six of 10 patients with HSVE and a noticeable anterograde memory impairment in the four others. However, in that study memory impairment was an inclusion criteria, which explains the abundant findings. Only a few studies have described mild forms of HSVE.

The neuropsychological assessment was carried out about one month after the onset of symptoms. The cognitive status cannot be regarded as final at that stage, and therefore we continued to follow up the patients to see whether the patients later became employed or retired. Almost half of the patients with HSVE, along with 89% of the non-HSVE patients, were eventually able to return to work. Although neuropsychological findings and psychiatric symptoms may be moderate to severe during the first weeks and months after the onset, improvement takes place within the first year and the outcome of HSVE may be more favourable than has been reported previously.

The good outcome in HSVE is also reflected in the fact that the radiological findings in our patients were mostly unilateral. This is by contrast with previous neuropsychological studies as well as MRI findings, which suggested that the damage in HSVE is nearly always bilateral. Progression of the lesion from unilateral to bilateral used to be common, but after the introduction of acyclovir treatment such advanced cases have become rarer. Unilateral findings, resulting in only mild neuropsychological sequelae, have been reported in other studies. The neuropsychological profile in some of our patients suggested bilateral damage, which was not detected in neuro-radiological imaging. Repeated MRI was not obtained in all patients, and minor lesions may have gone unseen. However, pronounced asymmetry was evident.

We think that the good outcome in our series is due to the fact that acyclovir medication was initiated very early, during the first four days of the onset in 12 of 17 patients. We did not wait for the HSVE diagnosis to be confirmed, but started medication at the mere suspicion of HSVE. Treatment latencies of less than four days have been reported to correlate with a favourable outcome.

We used clinically available standard CSF and serum laboratory tests for establishing the aetiologiical diagnosis. The retrospective diagnosis of HSVE was based on the rise in the antibody titres in the CSF and a pathological serum:CSF antibody ratio. Simultaneous rise in serum antibody titres was considered confirmatory. The same methods performed by the same laboratory have been used in previous epidemiological studies. These methods have also been widely used by others. The problems in laboratory verification of HSVE have been known for decades and biopsy has been suggested as the only reliable method. As acyclovir treatment is safe and controversy over the risks and benefits of biopsy exist, biopsy samples were not taken in our patients. Recently, the PCR technique has been proved reliable in the diagnosis and this method was used as soon as it became available to us.

This study did not include all patients treated for acute encephalitis in the Department of Neurology. It consisted of those referred for neuropsychological examination. Patients who died in the early phase were not included. On the other hand, a few patients without specific aetiologiical diagnosis who were discharged rapidly due to mild course of disease were also left out. Therefore, the possible bias in the inclusion of cases is bidirectional and probably does not distort the results. Also the fact that only specified aetiologies were included in the analyses might produce error. However, the patients with a specified encephalitis had neither more nor less cognitive defects than the patients with non-specified encephalitis, and the percentage of patients later returning to work was similar in these groups.

Table 6 gives the relevant medical literature concerning non-herpetic aetiologies. Reports on the cognitive status are scant and often limited to the acute stage. Neuropsychological assessment has usually not been made. Outcome also varies, and whereas reports from earlier decades often present fatal cases, more recent reports include total recoveries. In our series almost all patients with influenza B, Mycoplasma pneumoniae, rubella, and TBE virus encephalitis had no cognitive sequelae. One patient with influenza B virus and both patients with rotavirus encephalitis had resid-
Cognitive impairment after acute encephalitis: comparison of herpes simplex and other aetiologies


Cognitive impairment after acute encephalitis: comparison of herpes simplex and other aetiologies.

L Hokkanen, E Poutiainen, L Valanne, O Salonen, M Iivanainen and J Launes

*J Neurol Neurosurg Psychiatry* 1996 61: 478-484
doi: 10.1136/jnnp.61.5.478

Updated information and services can be found at:
http://jnnp.bmj.com/content/61/5/478

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/